Literature DB >> 34079094

Infographic: Slow-release dexamethasone in proliferative vitreoretinopathy (PVR).

I Mostafa1, M Al-Zubaidy1, A Ghareeb1, A Song1, A Mehta1, D Murphy1, S Sadiq1, N Tzoumas1, D H Steel2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34079094      PMCID： PMC8807709          DOI： 10.1038/s41433-021-01532-y

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN： 0950-222X            Impact factor:   3.775


× No keyword cloud information.
The slow-release dexamethasone in proliferative vitreoretinopathy (PVR) prospective, randomized controlled clinical trial showed that a slow-release Dexamethasone injection given at the time of vitrectomy surgery and repeated at the time of oil removal does not increase the anatomic success rate at 6 months in eyes with rhegmatogenous retinal detachment with grade C PVR. There was also no change in visual acuity, however there was a statistical reduction in cystoid macular oedema. CI confidence interval. Reference to original study: Banerjee, P. et al., 2017. Slow-Release Dexamethasone in Proliferative Vitreoretinopathy. Ophthalmology, 124(6), pp.757–767.
  1 in total

1.  EGF Receptor Signaling Modulates YAP Activation and Promotes Experimental Proliferative Vitreoretinopathy.

Authors:  Wei Zhang; Jing Li
Journal:  Invest Ophthalmol Vis Sci       Date:  2022-07-08       Impact factor: 4.925
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.